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PROPERDIN : BINDING TO C3b AND STABILIZATION OF
THE C3b-DEPENDENT C3 CONVERTASE*
BY DOUGLAS T. FEARONf AND K. FRANK AUSTEN
(From the Departments ofMedicine, Harvard Medical School and Robert B . BrighamHospital,
Boston, Massachusetts 02120)
Activated properdin (P),' a gamma globulin with an estimated mol wt of
223,000 daltons and an isoelectric point of greater than 9.5, has been purified
free of other serum proteins and observed to consist of four apparently identical
subunits of45,000 daltons each (8, 9) . P eluted from azymosan-serum complex or
purified from the euglobulin obtained from serum at pH 5 .4 interacts with
normal serum in the absence of zymosan, resulting in cleavage of C3 and B (9,
10) . Miiller-Eberhard and Gotze (6) have showed that the hydrazine-sensitive
factor (factor A) of the properdin system is C3 and that its major cleavage
product, Cab, interacts with B and D to form a C3b-dependent C3 convertase .
Formation of this convertase on the surface ofan erythrocyte, EAC43, permitted
stoichiometric hemolytic titrations of B and D to be performed (5, 11) and
revealed that P profoundly augmented the number of effective convertase sites
formed (12) . This action, previously attributed to a capacity ofP to convertD to
D, is shown now to be the result of binding of P to C3b with concomitant
retardation in decay of the C3b-dependent convertase .
Materials and Methods
Functionally pure guinea pigC1 andC2 were prepared as described (13) . Human C3 (14, 15) and
B (4)were purified to homogeneity as assessed by alkaline disc gelelectrophoresis andquantitated
by radial immunodiffusion against monospecific antisera . D was purified from citrated plasma
whichwas adjusted to pH 7.8, dilutedwith 0.0035M P0,, 0.002MEDTA, pH 7 .8, to a conductivity
of 5 mS at 4°C and applied directly to quaternary aminoethyl (QAE) Sephadex A-50 (Pharmacia
Fine Chemicals, Inc., Piscataway,N. J.) that hadbeen equilibrated with thePO,buffer brought to
5 mS by addition of NaCl . 1) eluted at 7 mS and was further purified by gel filtration twice on
Sephadex G-75 Superfine . The final preparation of D had no detectable trypsin-activable D
* Supported by grants AI-07722, AI-10356, AM-05577, and RR-05669 from the National Insti-
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$ Postdoctoral fellow of the Helen Hay Whitney Foundation .
' In the nomenclature for the alternative pathway the components are designated by capital
letters, with a bar over the letter indicating the active factor . B (1) is the properdin factor which
also has been termed C3 proactivator (2) and glycine-rich beta glycoprotein (3); D (4,5) is also
termed precursor of C3 proactivator convertase (6) ; factor A (1) is nowknownto be C3 (6) ; and P is
the symbol for properdin (7) .
Other abbreviations used in this paper: C-EDTA, rat serum diluted in GVB-EDTA ; DFP,
diisopropylphosphofluoridate ; DGVB", GVB+' plus dextrose ; GVB", gelatin veronal-buffered
saline with Mg" and Cal' ; QAE, quaternary aminoethyl ; Z, average number of hemolytic sites
per cell .
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activity, and exhibited asingle band on alkaline disc gel electrophoresis. D protein concentration
was estimated by Folin analysis (16) . P was isolated from the euglobulin fraction of citrated
plasma at pH 6.0 by chromatography on QAE Sephadex, sulphopropyl Sephadex, and Sephadex
G-200(12). Thefinalproduct exhibiteda single band on acidic disc gel electrophoresis andinduced
cleavage ofC3 and Bwhen addedto serumin the absenceof zymosan. P wasquantitated by radial
immunodiffusion (12).
Isotonic veronal-buffered saline containing 0.1% gelatin, 5 x 10-' M Mg", and 1.5 x 10-' M
Ca" (GVB++); half-isotonic gelatin veronal buffer with dextrose (DGVB"); and GVB in which
cations were omitted and containing 0.04 M EDTA (GVB-EDTA) were used as diluents for
hemolytic assays (13). Tube andmicrotiter platehemolytic assays for B, D, and trypsin-activable
Dwere performed (5, 11, 12, 17) with ratserumdiluted 1:15in GVB-EDTA (C-EDTA) as thesource
ofC3-C9. Activity determinations obtained by tube titration areexpressed as theaverage number
of hemolytic sites per cell (Z) and microtiter plate titrations are expressed as CH50 units per
milliliter. Dhsopropylphosphofluoridate (DFP) was obtained from Aldrich Chemical Co., Inc.,
Milwaukee, Wis.
Results
Capacity of Properdin to Increase the Hemolytic Titer of I) and B.
￿
To
examine whether P and trypsin were acting upon the same factor, plasma
obtained from blood collected into hexadimethrine and EDTA (5) was chromato-
graphed on QAE Sephadex as for isolation of I), and fractions were assayed for
D, trypsin-activable D, andfor the activity enhanced by P. Trypsin-activable D
activity eluted at 5.8 mS while P-inducible activity was found only in fractions
containing D which eluted with peak activity at 6.8 mS. To assess further
whetherthe expression of P was dependent on D activity, 5 gg D, purified to give
a single band on disc gel electrophoresis and free of trypsin-activable D, was
incubated with 5 x 10`3 M DFP or DGVB++ for 30 min at 37°C, extensively
dialyzed, and assayed for residual I) activity, with and without 1 Fig P/108
EAC43. D incubated in DGVB++ contained 0.08 U/ng alone and 1 U/ng in the
presence of P, while I) treated with DFP exhibited 0.007 U/ng alone and 0.086
U/ng with P. Thus, the P-enhanceable activity, which is DFP-sensitive and
separable from trypsin-activable D, is I).
To assess the capacity of P to increase the titer of a set, limited amount ofB in
the presence of excess D and to establish a standard assay for P, 1 x 10' EAC43
with 10 ng D, 0.16 ng B, and variable amounts of P in 0.2 ml DGVB++ were
incubated for 30 min at 30°C . After addition of 0.3 ml C-EDTA and further
incubation for 60 min at 37°C, 1.5 ml saline was added to each reaction mixture,
the extent of hemolysis was determined, and the Z was calculated . In the
absence of P, 0.16 Z were generated and the presence of increasing amounts of
properdin was associated with a linear increase in the number ofhemolytic sites
per cell (Fig . 1). In the absence of B, no hemolytic sites were formed, so that this
activity of P cannot be attributed to contamination with B. In subsequent
hemolytic titrations, P activity is expressed as the increase in Z achieved over
that obtained with EAC43, limited B and excess D alone; reaction mixtures
containing B and D alone always generated less than 0.2 Z.
Binding of P to EAC43. 1 x 10' EAC43, 0.14 ng B, and 10 ng D were
incubated with or without 10 ng P in 0.2 ml DGVB++ for 30 min at 30°C, followed
by addition of C-EDTA to bring the hemolytic reaction to completion; the
activity of 10 ng P was 1.50 Z. An additional 5 x 10' EAC43 were incubated with
50 ng P in 0.5 ml DGVB++ for 10 min at 15°C, after which the reaction mixture858
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Hemolytic activity (Z) generated during incubation of EAC43, D, constant limited
B, and variable amounts of P .
was centrifuged, the supernate was removed, and the erythrocytes were washed
twice in ice-cold DGVB ++ . Development of the hemolytic sites on 1 x 10' washed
erythrocytes with 0.14 ng B and 10 ng D resulted in generation of 1 .14 Z above
that obtained with cells not exposed to P, while hemolytic assay of 0 .1 ml of the
supernate yielded 0.13 Z of residual P activity . Thus, of the total P activity
initially available, 7617,- bound to EAC43, creating EAC43P, with 20% recovered
in the supernate .
The specificity of P binding for an intermediate bearing C3b was examined
with EAC4 and EAC43 . 20 ng P were incubated alone or with 2 x 10'EAC4 or
EAC43, ranging from 1 .25 x 10 6 to 2 x 10' in 0.2 ml DGVB++ for 10 min at 15°C,
after which the reaction mixtures were centrifuged, and the supernates removed
and assayed for P as in the previous experiment . P input was 0.64 Z and an
identical amount was recovered in the supernate of the reaction mixture contain-
ing 2 x 10'EAC4 (Fig . 2) . In contrast, incubation ofP with increasing numbers
of EAC43 resulted in a dose-related removal of P activity plateauing at 85%
depletion by 1 x 10' EAC43 .
The kinetics of binding of P to EAC43 at 15°C was compared to that at 0°C
because of the failure ofP in serum to bind to zymosan at 0°C (7). Samples of 1 x
10' EAC43 in 0.1 ml DGVB }+ at either 0°C or 15°C were added to 10 ng P in 0 .1
ml DGVB++ equilibrated at the appropriate temperature, and incubated at 0°C
or 15°C for up to 20 min . The reactions were stopped by the addition of 5 ml ice-
cold DGVB++ , immediate centrifugation at 0°C, and washing twice with
DGVB++ . The erythrocyte intermediates, and EAC43 that had been incubated
with DGVB++ alone, were each resuspended in 0.2 ml DGVB ++ containing 0.14
ng B and 10 ng 1) and then lysed with C-EDTA . Binding of P, as assessed by
incremental lysis, occurred rapidly and was complete in 5 min at 15°C and in 10
min at 0°C. No significant difference in the amount of P activity bound was
apparent at these two temperatures and there was no decay in 20 min(Fig . 3) .
Binding of P was compared in GVB++ and GVB-EDTA to examine the cation
requirement . Samples of 1 x 10' EAC43 were incubated for 10 min at 15°C with
10 ng P in 0.2 ml of GVB++ or GVB-EDTA . The intermediates were washed
once with their initial buffers and twice with ice-cold DGVB++, and assayed forZ
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Depletion of supernatant P by incremental concentrations of EAC43 (") as com-
pared to 2 x 10' EAC4 (0),
FiG. 3.
￿
Kinetics of formation of EAC43P (Z) at 4°C and 15°C.
cell-bound P activity. 0.86 Z and 0.88 Z ofP activity bound to EAC43 in GVB{{
and GVB-EDTA, respectively.
Stabilization ofthe Hernolytically Active Site on EAC43B by P.
￿
The capacity
of P to bind to EAC43 and to increase by more than 10-fold the hemolytic
efficiency of a setand limited amount of B prompted an analysis of the effect o£P
on the half-life (t,,2) of the Cab-dependent C3 convertase . 4 x 108 EAC43, 80 ng
B, and 0.4 trg D in 8 ml DGVB+' were incubated for 30 min at 30°C to generate
EAC43B. The reaction mixture wasdivided into four equal portions which were
centrifuged at 4°C, the supernates were removed, and the cells washed once in
ice-cold DGVB++. The washed EAC43B were resuspended at 30°C in 2 ml GVB-
EDTA, or GVB-EDTA containing either 500, 100, or 20 ng P. Incubation was
continued at 30°C during which 0.2-ml sampleswere removed from each reaction
mixture at timed intervals and added to 0.3 ml C-EDTA to assess residual
convertase sites. The hemolytically active site on EAC43B decayed with a tl12 of
4 min in the absence ofP, while thepresence ofP prolonged the tQ up to 30 min860
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in a dose-related manner (Fig . 4) . There was no detectable lag in the stabilizing
effect ofP so that decay was first order in each reaction mixture, and the pres-
ence of P did not increase the number of active sites available at zero time .
Washing the stabilized intermediate at 4°C in GVB-EDTA during the decay
analysis did not alter the previously established decay rate upon subsequent
resuspension and decay .
The capacity of P introduced into the fluid phase to stabilize C3B raised the
question of whether or not P previously bound to C3b could transfer so as to
achieve thesame result. Donorcells were formed by interacting three batches of
1 x 10' EAC43 with 400 ng P, 200 ng P, or buffer for 10 min at 15°C, after which
the intermediates were washed twice with ice-cold DGVB++ and resuspended in
1 ml GVB-EDTA at 30°C . Recipient EAC43B were generated by incubating
3 x 10 11 EAC43 with 30 ng B and 0.3 tLgD in 6 ml DGVB'' for 30 minat 30°C . The
recipient cells were washed once in DGVB"+, resuspended in 3 ml GVB-EDTA
at 30°C, and divided into three equal portions, each of which received 1 ml con-
taining 1 x 10' EAC43P or EAC43. Incubationwas continued at 30°C and 0.2-ml
samples containing 1 x 10' recipient cells and 1 x 10' donor cells were with-
drawn at timed intervals, added to 0.3 ml C-EDTA, and incubated for50 min at
3T°C to develop the recipient cell convertase sites . The t112 ofEAC43B interacted
with EAC43 was 4.5 min, while the t2 of EAC43B interacted with EAC43P,
which had been formed with 200 and 400 ng P, was prolonged to 24 and 60 min,
respectively (Fig . 5, left panel) .
To confirm that stabilization ofthe recipient convertase wasdirectly relatedto
the quantity of P made available by the donor cells, a fixed quantity of Pwas
interacted with two different concentrations of donor cells, which were then
analyzed for their capacity to stabilize EAC43B . 4 x 10' EAC43 and 1 x 10'2.0
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(Left panel) Decay of EAC43B interacted with EAC43 (0) or EAC43P generated
with 200(0) and400 ng P(O), respectively . (Right panel) Decayof EAC43B interacted with
4 x 10' EAC43 (0), 1 x 10' EAC43P (0) generated with 200 ng P, or 4 x 10' EAC43P (O)
generated with 200 ng P .
EAC43 were incubated with 200 ng P in 1 ml DGVB++ for 10 min at 15°C, while 4
x 10' EAC43 were incubated with DGVB++ alone . After washing in ice-cold
DGVB++ and resuspension in 1 ml GVB-EDTA at 30°C, the donor cells were
added to 1 x 108 EAC43B in 1 ml GVB-EDTA, and transfer was assessed exactly
as above . EAC43B incubated with EAC43 decayed with a t1,2 of 4 min, while
addition ofEAC43P, either 1 x 10' or 4 x 10' formed with the same amount of P,
resulted in a comparable degree of stabilization, extending the t1,2 to 19 and 20
min, respectively (Fig . 5, right panel) . Since stabilization of the convertase site
on EAC43B varied with the amount of bound P made available and was
independent of the number of EAC43P, transfer of P to EAC43B must have
occurred .
Discussion
The capacity ofP to augment the hemolytic activity of D was appreciated by
three different approaches : chromatographic fractions of plasma that contained
D exhibited enhancement in their hemolytic titer when assayed in the presence
of P, while fractions containing trypsin-activable D were not augmented ; the P
enhancement of D activity was fully apparent with D that presented a single
band on alkaline disc gel electrophoresis coinciding with the position from which
D activity was eluted in replicate unstained gels ; and treatment of purified D
with DFP reduced both the D titer and the net increment observed with P by
92% . The previous conclusion that P permits the hemolytic assay of D by
conversion to D (12) is not supported and is now attributed to the presence of less
than 10% D in the preparations of D . The capacity of P to increase also the
hemolytic activity oflimited B (Fig . 1) is consistent with the view that the action86)2
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of P is not on an individual component but on the product of the interaction of
several factors.
Although P-dependent augmentation of the hemolytic titer of a set, limited
amount ofB in the presence ofexcessD was appreciated initially by introduction
ofP into the fluid phase (Fig. 1), the same result occurred when P was bound to
EAC43 before interaction with B and I). P did not bind to EAC4, and the extent
of binding to EAC43 was related to the number of cells employed for adsorption
(Fig. 2). Furthermore, the sum of the P activity bound to EAC43 and that
remainingin the supernate was equal to the initial input. Formationof EAC43P
was slightly more rapid at 15°C than at 0°C, but was quantitatively equal at
these temperatures (Fig. 3), and did not require divalent cations. In contrast to
these findings are the temperature and Mg" requirements (7) for binding of P
in serum to zymosan, which probably relate to the conditions necessary for
initial cleavage of C3 and binding of Cab to zymosan.
The mechanism by which P augmented the hemolytic activity of either B or D
was elucidated when P was shown to stabilize the otherwise labile convertase
site on EAC43B, extending its t1,2 up to 10-foldin a dose-responsefashion (Fig. 4).
The fact that each intermediate exhibited the same number of initial sites,
irrespective of its subsequent rate of decay, indicates that the effect ofP is to
stabilize the cell-bound convertase rather than to uncover additional convertase
sites. The additional observation that decay ofconvertase sites was firstorder at
each dose of P suggests that a limited amount ofP interacts equally among all
sites. The reversible binding ofP to Cab on EAC43 was appreciated by transfer
from EAC43P to EAC43B with the stability of the resulting intermediate,
EAC43PB, being dependent on the amount of cell-bound P available for transfer
rather than the concentration of donor cells (Fig. 5). The capacity ofP to bind to
C3b and stabilize C3B contrasts with the inhibitory effect of the Cab inactivator
on formation of this amplification convertase (15, 18).
Summary
A function ofP in the alternative complement pathway is to prolong the first
order decay of the hemolytic sites on EAC43B in a dose-dependent manner . As
the number of initial convertase sites is not changed, even when activated
properdin (P) increases the t1,2 10-fold or more, P acts to stabilize rather than to
uncover additional sites. P binds to EAC43 to generate EAC43P in a reaction
that proceeds slightly more rapidly at 15°C than at 0°C, but reaches the same
plateau and does not require divalent cations. The presence ofP on EAC43P not
only stabilizes the convertase subsequently formed on that cell, but, alterna-
tively, permits transfer to convertase sites on other cells with the stabilityof the
recipient intermediate being dependent on the P available for transfer. The
capacity ofP to bind to C3b and stabilize C3B contrasts with the inhibitory effect
of the Cab inactivator on formation of this amplification convertase.
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